This regimen was shown in clinical trials to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose, according to AstraZeneca.
Hyderabad: Employability is not the only purpose of education, it should facilitate a solution to the problems faced by the society said Prof Mohammad Talib, Oxford Centre for Islamic Studies, Oxford University, UK. Addressing online valedictory session of the fourth National Urdu Social Sciences Congress ‘Social Sciences – Decline and Resurgence’ organised by Maulana Azad […]
Modi began his three-city visit on Saturday to review coronavirus vaccine development work by going to pharma major Zydus Cadila's manufacturing facility near Ahmedabad in the morning.
Zydus Cadila had announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus.
The team is also testing whether the vaccine stops people developing COVID-19 in larger Phase 3 trials and early results from this crucial stage are expected in the coming weeks.
According to the study, published in 'Behavioural Ecology', as a pathogen spreads across a population, changes in social behaviour can alter how the disease spreads
